Structure, function, and allosteric modulation of NMDA receptors

Kasper B. Hansen¹, Feng Yi¹, Riley E. Perszyk², Hiro Furukawa³, Lonnie P. Wollmuth⁴, Alasdair J. Gibb⁵, and Stephen F. Traynelis²

NMDA-type glutamate receptors are ligand-gated ion channels that mediate a Ca²⁺-permeable component of excitatory neurotransmission in the central nervous system (CNS). They are expressed throughout the CNS and play key physiological roles in synaptic function, such as synaptic plasticity, learning, and memory. NMDA receptors are also implicated in the pathophysiology of several CNS disorders and more recently have been identified as a locus for disease-associated genomic variation. NMDA receptors exist as a diverse array of subtypes formed by variation in assembly of seven subunits (GluN1, GluN2A-D, and GluN3A-B) into tetrameric receptor complexes. These NMDA receptor subtypes show unique structural features that account for their distinct functional and pharmacological properties allowing precise tuning of their physiological roles. Here, we review the relationship between NMDA receptor structure and function with an emphasis on emerging atomic resolution structures, which begin to explain unique features of this receptor.

Introduction

The vast majority of the excitatory neurotransmission in the central nervous system (CNS) is mediated by vesicular release of glutamate, which activates both pre and postsynaptic G-protein-coupled metabotropic glutamate receptors and ionotropic glutamate receptors (iGluRs). iGluRs are ligand-gated cation channels that are divided into three major structurally distinct functional classes: the α-amino-3-hydroxy-5-methyl-4-isoxasolepropionic acid (AMPA) receptors, kainate receptors, and NMDA receptors (Traynelis et al., 2010; Fig. 1A). The nomenclature for these functional classes was initially based on the activating agonist, and subsequent molecular cloning revealed cDNAs encoding multiple subunits within the three classes of iGluRs. An intriguing fourth class of iGluRs (GluD1-2) have structural resemblance to AMPA and kainate receptors but do not function as ion channels under normal circumstances (Yuzaki and Aricescu, 2017). Several unique properties distinguish NMDA receptors from other glutamate receptors, including voltage-dependent block by extracellular Mg²⁺, high permeability to Ca²⁺, and the requirement for binding of two coagonists, glutamate and glycine (or d-serine), for channel activation (Traynelis et al., 2010). These features have a profound impact on the physiological roles of NMDA receptors and have therefore been the topic of intense investigation.

At central synapses, glutamate release activates iGluRs that mediate an inward current and thereby depolarize the postsynaptic neurons. These excitatory postsynaptic currents (EPSCs) can be described primarily by two temporally distinct components corresponding to activation of AMPA and NMDA receptors. AMPA receptors mediate a synaptic current with rapid rise time and decay, whereas NMDA receptor activation mediates a current that activates more slowly with a time course that endures for tens to hundreds of milliseconds (Hestrin et al., 1990; Sah et al., 1990; Trussell et al., 1993; Geiger et al., 1997; Fig. 1B). At rest, the NMDA receptor pore is strongly blocked in a voltage-dependent manner by extracellular Mg²⁺, but this block can be released by the depolarization that accompanies rapid activation of AMPA receptors, particularly when there is a series of closely spaced synaptic events (Fig. 1C). Thus, the current mediated by NMDA receptors is dependent on both the membrane potential and frequency of synaptic release, rendering these receptors coincidence detectors that respond uniquely to simultaneous presynaptic release of glutamate and postsynaptic depolarization with a slow synaptic current that allows substantial influx of external Ca²⁺ into the dendritic spine (Bourne and Nicoll, 1993; Seeburg et al., 1995; Nevian and Sakmann, 2004). This increase in intracellular Ca²⁺ serves as a signal that leads to multiple changes in the postsynaptic neuron, including changes that ultimately produce either short-term or long-term changes in synaptic strength (Lau and Zukin, 2007; Holtmaat and Svoboda, 2009; Traynelis et al., 2010; Higley and Sabatini, 2012; Zorumski and Izumi, 2012).

© 2018 Hansen et al. This article is distributed under the terms of an Attribution–NonCommercial–Share Alike—No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–NonCommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
Paoletti et al., 2013; Volianskis et al., 2015). The nature of these changes (e.g., increased or decreased synaptic strength) depends on the frequency and duration of synaptic NMDA receptor activation (Citri and Malenka, 2008; Granger and Nicoll, 2013), thereby providing the brain with a mechanism for encoding information (Hunt and Castillo, 2012; Morris, 2013).

NMDA receptors are unique among synaptic receptors in their requirement for the binding of two agonists, glutamate and glycine (or D-serine: Johnson and Ascher, 1987; Kleckner and Dingledine, 1988; Benveniste and Mayer, 1991; Clements and Westbrook, 1991, 1994). Synaptic NMDA receptors are temporally controlled by the synaptic release of glutamate for activation, because extracellular glycine (or D-serine) is thought to be continuously present at fairly constant concentration. The distinction of glycine or D-serine appears to depend on brain region in addition to the subcellular localization of the receptor (Wolosker, 2007; Oliet and Mothet, 2009; Mothet et al., 2015). For example, some data suggested that D-serine is the dominant coagonist at synapses, with glycine being more important at extrasynaptic sites (Papouin et al., 2012). Although this is an intriguing subdivision, more work will be required to confirm this idea as a general principle. Furthermore, glycine and D-serine are unlikely to be present at concentrations that saturate the coagonist binding site (Berger et al., 1998; Bergeron et al., 1998; Karakas and Furukawa, 2014; Lee et al., 2014; Fig. 2). However, subunit assembly and physiological roles of the glycine-binding GluN3 subunits remain elusive, and the GluN3 subunits will not be considered in this review (Cavara and Hollmann, 2008; Henson et al., 2010; Low and Wee, 2010; Pachernegg et al., 2012; Kehoe et al., 2013; Pérez-Otaño et al., 2016).

When glutamate is released into the synaptic cleft, it reaches a high concentration (∼1.1 mM) for a brief duration of time, decaying with a time constant of ∼1.2 ms (Clements et al., 1992) as a result of diffusion and active removal of glutamate from the synaptic cleft by excitatory amino acid transporters (i.e., glutamate transporter; Divito and Underhill, 2014). In the synaptic cleft, glutamate will bind to AMPA (and/or kainate) and NMDA receptors, inducing the necessary conformational changes that trigger opening of the ion channel pore, a process referred to as gating. The NMDA receptor–mediated component of the EPSC continues to pass current for tens to hundreds of milliseconds after synaptic glutamate is removed (Lester et al., 1990), which is in part a reflection of agonist binding affinity but also because the receptor activation mechanism involves pregating steps as well as repeated transitions between glutamate-bound open and closed conformational states until glutamate eventually unbinds and the EPSC is terminated (Lester et al., 1990; Lester and Jähn, 1992; Erreger et al., 2005a; Zhang et al., 2008). The functional consequences of the gating reaction mechanism are strongly dependent on the identity of the GluN2 subunit (Monyer et al., 1992, 1994; Vicini et al., 1998; Wyllie et al., 1998). The four different GluN2 subunits thus create substantial diversity among NMDA receptors, and assembly of receptors that contain different GluN2 subunits with distinct properties allows tuning of the synaptic response time course and variation in parameters that control synaptic strength and plasticity. This diversity exerts

### Subunit composition of NMDA receptors

Seven genes encode the NMDA receptor subunits: a single GRIN1 gene encodes GluN1, four GRIN2 genes encode GluN2A–D, and two GRIN3 genes encode GluN3A–B (Traynelis et al., 2010). All known NMDA receptors are heterotetrameric assemblies of subunits, which together form a central ion channel pore with striking similarity to an inverted potassium channel. The stoichiometry of the NMDA receptor has been definitively shown to be two glycine-binding GluN1 and two glutamate-binding GluN2 subunits (i.e., GluN1/2 receptors; Ulbrich and Isacoff, 2007; Karakas and Furukawa, 2014; Lee et al., 2014; Fig. 2). However, subunit assembly and physiological roles of the glycine-binding GluN3 subunits remain elusive, and the GluN3 subunits will not be considered in this review (Cavara and Hollmann, 2008; Henson et al., 2010; Low and Wee, 2010; Pachernegg et al., 2012; Kehoe et al., 2013; Pérez-Otaño et al., 2016).

When glutamate is released into the synaptic cleft, it reaches a high concentration (∼1.1 mM) for a brief duration of time, decaying with a time constant of ∼1.2 ms (Clements et al., 1992) as a result of diffusion and active removal of glutamate from the synaptic cleft by excitatory amino acid transporters (i.e., glutamate transporter; Divito and Underhill, 2014). In the synaptic cleft, glutamate will bind to AMPA (and/or kainate) and NMDA receptors, inducing the necessary conformational changes that trigger opening of the ion channel pore, a process referred to as gating. The NMDA receptor–mediated component of the EPSC continues to pass current for tens to hundreds of milliseconds after synaptic glutamate is removed (Lester et al., 1990), which is in part a reflection of agonist binding affinity but also because the receptor activation mechanism involves pregating steps as well as repeated transitions between glutamate-bound open and closed conformational states until glutamate eventually unbinds and the EPSC is terminated (Lester et al., 1990; Lester and Jähn, 1992; Erreger et al., 2005a; Zhang et al., 2008). The functional consequences of the gating reaction mechanism are strongly dependent on the identity of the GluN2 subunit (Monyer et al., 1992, 1994; Vicini et al., 1998; Wyllie et al., 1998). The four different GluN2 subunits thus create substantial diversity among NMDA receptors, and assembly of receptors that contain different GluN2 subunits with distinct properties allows tuning of the synaptic response time course and variation in parameters that control synaptic strength and plasticity. This diversity exerts

---

**Figure 1. Functional classes of iGluRs.** (A) iGluRs are divided into AMPA, kainate, and NMDA receptors with multiple subunits cloned in each of these functional classes. (B) EPSCs from central synapses can be divided into fast AMPA or slow NMDA receptor–mediated components in the absence of Mg^2+ using the AMPA receptor antagonist CNQX or the NMDA receptor antagonist AP5. The figure is adapted from Traynelis et al. (2010). (C) The relationships between NMDA receptor current response and membrane potential (i.e., holding potential) in the presence and absence of 100 µM extracellular Mg^2+ reveal the voltage-dependent Mg^2+ block, which is relieved as the membrane potential approaches 0 mV (i.e., with depolarization). Data are from Yi et al. (2018).
The glycine-binding GluN1 subunit

The GluN1 subunit, which binds glycine and d-serine, is an obligatory subunit in all functional NMDA receptors and is therefore widely expressed in virtually all central neurons. Three exons in the GluN1 subunit can be alternatively spliced to produce eight different isoforms (Durand et al., 1992; Nakanishi et al., 1992; Sugihara et al., 1992; Hollmann et al., 1993). Exon 5 encodes 21 amino acids in the GluN1 amino-terminal domain (ATD), exon 21 encodes 37 amino acids in the carboxyl-terminal domain (CTD), and exon 22 encodes 38 amino acids in the CTD. Deletion of exon 22 eliminates a stop codon and produces a frameshift, which results in the inclusion of 22 alternative amino acids in the mature polypeptide chain. The GluN1 splice variants show variation in regional and developmental profiles (Laurie and Seeburg, 1994; Zhong et al., 1995; Pahk and Williams, 1997; Mott et al., 1998; Rumbaugh et al., 2000; Yi et al., 2018). Alternative splicing of exons 21 and 22 changes the amino acid composition of the intracellular GluN1 CTD, which interacts with PSD-95, calmodulin, and the neurofilament subunit NF-L (Traynelis et al., 2010). These proteins are involved in surface trafficking and anchoring of receptors at synaptic sites, and alternative splicing of exons 21 and 22 influences cell surface distribution of NMDA receptors (Scott et al., 2001, 2003; Mu et al., 2003; Wenthold et al., 2003). The CTD of GluN1 is a binding site for calmodulin (Ehlers et al., 1996; Iacobucci and Popescu, 2017b), as well as a target of kinases and phosphatases (Tingley et al., 1993, 1997). The relationships between functional roles and structural features of the residues encoded by GluN1 exon 21 and 22 are not yet fully understood.

The glutamate-binding GluN2 subunits

The four glutamate-binding GluN2A-D subunits provide the CNS with a means of controlling NMDA receptor properties as a function of developmental period and brain region (Fig. 3 A). Many studies have described the variation in expression profiles of these subunits, which ultimately control important features of the synaptic NMDA receptor component (Monyer et al., 1992, 1994; Watanabe et al., 1992; Ishii et al., 1993; Akazawa et al., 1994; Zhong et al., 1995). Attempts to pharmacologically control specific NMDA receptor subtypes have, not surprisingly, focused on the development of small molecules that can distinguish between the GluN2 subunits (Ogden and Traynelis, 2011; Strong et al., 2014; Vyklicky et al., 2014; Zhu and Paoletti, 2015; Hackos and Hanson, 2017; Burnell et al., 2018). These efforts are driven in part by the hope that GluN2 subunit–selective pharmacological probes will allow targeting of unique circuits at specific developmental periods to bring about a desired therapeutically beneficial effect.

Among the many differences in functional properties governed by the GluN2 subunit, several are particularly noteworthy (Erreger et al., 2004; Traynelis et al., 2010; Paoletti et al., 2013; Wylie et al., 2013; Glasgow et al., 2015). The potency of glutamate is influenced by the GluN2 subunits. For example, the EC50 for glutamate-activating NMDA receptors containing two GluN1 and two GluN2D subunits is more than fivefold lower (i.e., more potent) than that for GluN1/2A, whereas GluN1/2B and GluN1/2C receptors show intermediate EC50 values (Erreger et al., 2007; Chen et al., 2008; Hansen et al., 2008). The time course of deactivation after removal of glutamate, which controls the duration of the synaptic EPSC (Lester et al., 1990), varies over 100-fold for the different GluN2 subunits (Fig. 3 B). The time constants describing the exponential deactivation time course (τdecay) are ∼40–50 ms for GluN1/2A, ∼300–400 ms for GluN1/2B and GluN1/2C, and ∼4 s for GluN1/2D (Monyer et al., 1992; Vicini et al., 1998; Wylie et al., 1998; Yuan et al., 2009). Interestingly, intrareceptor allosteric interactions render the potency of glycine and d-serine at the GluN1 subunit sensitive to the identity of the GluN2 subunit (Sheinin et al., 2001; Chen et al., 2008; Dravid et al., 2010; Jessen et al., 2017; Maalonen et al., 2017). For example,
the potency of glycine at GluN1/2A receptors is ~10-fold less than at GluN1/2D receptors (Chen et al., 2008).

Multiple biophysical properties are also controlled by the GluN2 subunit. GluN1/2A and GluN1/2B have higher single-channel conductance than GluN1/2C and GluN1/2D receptors (Erreger et al., 2004; Traynelis et al., 2010; Paoletti et al., 2013; Wyllie et al., 2013; Glasgow et al., 2015; Fig. 3C). GluN1/2A and GluN1/2B also show higher Ca\(^{2+}\) permeability and are more sensitive to Mg\(^{2+}\) block than GluN1/2C and GluN1/2D (Monyer et al., 1992, 1994; Burnashev et al., 1995; Kuner and Schoepfer, 1996; Qian et al., 2005; Siegler Retchless et al., 2012). These biophysical differences are important, as the sensitivity to voltage-dependent Mg\(^{2+}\) block can influence the temporal window for spike timing-dependent plasticity (Nevian and Sakmann, 2004, 2006; Carter and Jahr, 2016). Furthermore, the probability that the channel will be open when all agonist-binding sites are occupied by agonists (i.e., the open probability) is strongly dependent on GluN2 identity (Fig. 3C). The open probability is ~0.5 for recombinant GluN1/2A, ~0.1 for GluN1/2B, and <0.02 for GluN1/2C and GluN1/2D (Erreger et al., 2004; Traynelis et al., 2010; Paoletti et al., 2013; Wyllie et al., 2013; Glasgow et al., 2015). The GluN2 subunits also control inhibition of NMDA receptors by endogenous modulators, such as protons and extracellular Zn\(^{2+}\) (Traynelis et al., 1995, 1998; Paoletti et al., 1997).

The amino acid sequence of the intracellular CTD is highly variable among GluN2 subunits, thereby producing pronounced differences in interaction sites for phosphatases, kinases, and proteins responsible for anchoring at synaptic sites and surface trafficking (Wenthold et al., 2003; Traynelis et al., 2010; Sanz-Clemente et al., 2013; Aman et al., 2014; Lussier et al., 2015). As a result of this variation, the GluN2 subunits therefore influence cell-surface expression, subcellular localization, and recycling/degradation of NMDA receptor subtypes.

**Diheteromeric and triheteromeric NMDA receptors**

The NMDA receptor subunits assemble into receptors with varying composition and distinct functional properties and roles in the CNS. At least two different GluN2 subunits are expressed in most neurons, and thus virtually all neurons have the opportunity to signal through triheteromeric NMDA receptors that contain two GluN1 and two different GluN2 subunits (Chazot et al., 1994; Sheng et al., 1994; Chazot and Stephenson, 1997; Luo et al., 1997; Cathala et al., 2000; Piña-Crespo and Gibb, 2002; Brickley et al., 2003; Jones and Gibb, 2005; Al-Hallaq et al., 2007; Rauner and Köhr, 2011; Tovar et al., 2013; Huang and Gibb, 2014; Swanger et al., 2015). Multiple lines of evidence support the expression of triheteromeric NMDA receptors of the GluN1/2A/2B,
NMDA receptor structure and function

All glutamate receptor subunits share a similar architecture that comprises four domains: a large extracellular ATD, a bilobed ABD, a pore-forming transmembrane domain (TMD), and an intracellular CTD (Fig. 4 A). The TMD is formed by three transmembrane helices (M1, M3, and M4) and a reentrant loop (M2). In iGluRs, the reentrant loop lines the intracellular portion of the ion channel pore, whereas elements of the third transmembrane segment (M3) form the extracellular region of the pore. Among NMDA receptor subtypes, the residues in the pore region, which influence ion permeation, are highly conserved. A key determinant of ion permeation, which controls divalent ion permeability and Mg2+ block, resides at the apex of the reentrant M2 loop and is often referred to as the Q/R/N site on the basis of amino acids at this position in AMPA, kainate, and NMDA receptors (Wollmuth, 2018).

The ATDs from each subunit adopt bilobed structures formed by the first ~350 amino acids that associate as back-to-side heterodimers between GluN1 and GluN2. The ATDs play important roles in assembly and strongly modulate NMDA receptor function (Atalason et al., 2007; Gießen et al., 2009; Yuan et al., 2009; Farina et al., 2011). Furthermore, the ATDs create binding sites for allosteric modulators, including extracellular Zn2+ and a diverse series of GluN2B-selective antagonists (exemplified by ifenprodil; Karakas et al., 2009, 2011; Romero-Hernandez et al., 2016; Tajima et al., 2016; Fig. 4 B).

The ABD is formed by the S1 and S2 segments of the polypeptide chain, which are separated by the M1, M2, and M3 segments. The ABDs form kidney-shaped bilobed structures that contain an upper lobe (D1) and a lower lobe (D2) with the agonist-binding site residing in the cleft between these two lobes (Fig. 4 A). The ABD structure, intra- and intersubunit interactions, and its influence on receptor function have been studied for more than two decades. More recently, crystallographic and cryo-EM data have provided the first glimpses of the domain organization of inactive and active GluN1/2B NMDA receptors, providing mechanistic hypotheses by which the different domains and their cognate ligands influence receptor function (Karakas and Furukawa, 2014; Lee et al., 2014; Tajima et al., 2016; Zhu et al., 2016; Regan et al., 2018; Song et al., 2018). We will consider each of these domains in more detail below.

Structure and function of GluN1 and GluN2 ABDs

Keinänen and colleagues were the first to demonstrate that recombinant glutamate receptor ABDs can be generated as soluble proteins by linking the S1 and S2 polypeptide sequences with an artificial peptide linker (Kuusinen et al., 1995; Arvola and Keinänen, 1996). Subsequent work by Gouaux and colleagues resulted in the first crystal structures of glutamate receptor ABDs (Armstrong et al., 1998; Armstrong and Gouaux, 2000). The water-soluble ABD proteins produced by this approach retain ligand-binding activities comparable to those in full-length glutamate receptors, indicating that structural integrity and characteristics of the agonist-binding pocket are retained in isolated ABDs. ABD structures for GluN1, GluN2, and GluN3 subunits have been solved in complex with agonists, antagonists, and allosteric modulators (Furukawa and Gouaux, 2003; Furukawa et al., 2005; Inanobe et al., 2005; Yao and Mayer, 2006; Yao et al., 2008, 2013; Vance et al., 2011; Hansen et al., 2013; Kvist et
al., 2013; Jespersen et al., 2014; Hackos et al., 2016; Volgraf et al., 2016; Yi et al., 2016; Lind et al., 2017; Romero-Hernandez and Furukawa, 2017). In addition to NMDA receptor subunits, numerous crystal structures for AMPA and kainate receptor subunits (Pøhlsgaard et al., 2011; Kumar and Mayer, 2013; Karakas et al., 2015) have provided insight into the mechanism underlying full and partial agonism, suggested molecular determinants of subunit selectivity, and demonstrated mechanism and binding pose for competitive antagonists.

The GluN2A ABD in complex with the GluN1 ABD provided the first structural information about a GluN1/GluN2 subunit interface within the NMDA receptor complex, in addition to the binding mode for glutamate and glycine between the two lobes (D1 and D2) of GluN2A and GluN1, respectively (Furukawa et al., 2005; Fig. 5 A). Multiple water molecules reside in close proximity to the agonists, and some form a hydrogen-bonding network that interacts with the ligand. The glycine-binding pocket in GluN1 is considerably smaller and more hydrophobic than the glutamate-binding pocket in GluN2 (Furukawa and Gouaux, 2003; Furukawa et al., 2005; Inanobe et al., 2005; Yao et al., 2008, 2013). Residues within the glutamate-binding pocket that make atomic contacts with agonists or competitive antagonists are mostly conserved in the GluN2 subunits, and it has therefore proven difficult to identify ligands that bind to this site with strong selectivity between the different NMDA receptor subtypes. However, recent crystallographic data have revealed the structural basis for binding of antagonists with modest selectivity (Lind et al., 2017; Romero-Hernandez and Furukawa, 2017). Selectivity in these cases is driven by space outside the conventional binding pocket that competitive antagonists can exploit in a GluN2-dependent manner (Fig. 5 B).

The residues at the heterodimer interface between the GluN1 and GluN2 ABDs modulate receptor function in several important ways. Three separate areas of contact between GluN1 and GluN2A can be seen in the ABD heterodimer crystal structures (referred to as sites I, II, and III; Furukawa et al., 2005; Fig. 5 A). Sites I and III consist of hydrophobic residues from both GluN1 and GluN2, and nonpolar interactions between these residues mediate ABD heterodimerization (Furukawa et al., 2005). The heterodimeric arrangement of GluN1 and GluN2A ABDs is similar to the homodimeric arrangement found in some AMPA and kainate receptors. In AMPA receptors, allosteric modulators such as cyclothiazide and aniracetam bind to sites equivalent to site I + III and site II, respectively, resulting in block of desensitization and slowing of deactivation speeds (Sun et al., 2002; Jin et al., 2005). The aromatic ring of Tyr535 in GluN1 has a positional overlap with that of aniracetam bound in AMPA receptors, therefore acting like a natural “tethered ligand” incorporated in the primary sequence (Furukawa et al., 2005). Consistently, mutations of Tyr535 in GluN1 alters deactivation time course of NMDA receptors, suggesting that the heterodimer interface can influence factors controlling deactivation, such as agonist dissociation or channel open time (Furukawa et al., 2005; Borschel et al., 2015). Recent crystallographic studies have shown that site II of the GluN1/2A ABD heterodimer contains the binding sites for both positive and negative allosteric modulators with strong selectivity for GluN2A (Hackos et al., 2016; Volgraf et al., 2016; Yi et al., 2016). Together, these results identify the heterodimer ABD
Figure 5. Crystal structures of NMDA receptor ABDs. (A) Structures of the soluble GluN1/2 ABD heterodimers reveal the subunit interface and back-to-back dimer arrangement of the ABDs. The structure shown here is for the GluN1/2A ABD heterodimer with bound glutamate and glycine shown as spheres (Protein Data Bank accession no. 5I57; Yi et al., 2016). The top view of the structure highlights sites I–III at the subunit interface. (B) Overlay of crystal structures of GluN1/2A ABD heterodimers in complex with glycine and either glutamate agonist (Protein Data Bank accession no. 5I57; Yi et al., 2016) or a competitive glutamate site antagonist (Protein Data Bank accession no. 5U8C; Romero-Hernandez and Furukawa, 2017). Activation of NMDA receptors requires agonist-induced ABD closure. Competitive antagonists bind the ABD without inducing domain closure, thereby preventing receptor activation. (C) Magnified views of the glutamate-binding site with bound GluN2A-preferring antagonists NVP-AAM077 (Protein Data Bank accession no. 5U8C; Romero-Hernandez and Furukawa, 2017) or ST3 (Protein Data Bank accession no. 5V7I; Lind et al., 2017). Schild analyses demonstrated that NVP-AAM077 has 11-fold and ST3 has 15-fold preference for GluN1/2A over GluN1/2B receptors (data adapted from Lind et al., 2017). The crystal structures reveal a binding mode in which NVP-AAM077 and ST3 occupy a cavity that extends toward GluN1 at the subunit interface, and mutational analyses show that the GluN2A preference of these antagonists is primarily mediated by four nonconserved residues (Lys738, Tyr754, Ile755, and Thr758) that do not directly contact the ligand but are positioned within 12 Å
NMDA receptors are sensitive to the redox potential, and reducing conditions can enhance NMDA receptor–mediated current responses (Aizenman et al., 1989; Tang and Aizenman, 1993; Köhr et al., 1994; Choi and Lipton, 2000). This sensitivity appears to be mediated by a pair of conserved cysteine residues (C744 and C798) within the GluN1 subunit (Sullivan et al., 1994; Choi et al., 2001). These two residues interact as a disulfide bond in the GluN1/2A ABD heterodimer structure, and reduction of this conformational constraint in GluN1, but not GluN2, enhances NMDA receptor function (Sullivan et al., 1994; Talukder et al., 2011). Several other disulfide bonds exist in ABD crystal structures of both GluN1 and GluN2 subunits, but functional effects of their reduction or oxidation have not yet been described (Takahashi et al., 2015).

Structures of the GluN1-GluN2A ABD heterodimer in complex with various agonists, partial agonists, and antagonists have suggested a structural basis for their modes of action (Furukawa and Gouaux, 2003; Furukawa et al., 2005; Inanobe et al., 2005; Vance et al., 2011; Hansen et al., 2013; Yao et al., 2013; Jespersen et al., 2014). Binding of glycine and glutamate to GluN1 and GluN2 ABDs, respectively, produces a rapid ABD rearrangement that involves reduction of the angle between the D1 and D2 lobes, producing a clamshell–like closure of the bilobed domain (Fig. 5 B). This agonist-mediated ABD closure triggers formation of hydrogen bonds between residues from the upper and lower lobes, which are hypothesized to stabilize the agonist-bound ABD structure (Kalbaugh et al., 2004; Paganelli et al., 2013). The energy provided by agonist binding and ABD closure triggers the receptor to undergo a series of conformational changes that ultimately open the ion channel pore. Thus, ABD closure that results from agonist binding is the initial conformational change that ultimately triggers the process of ion channel gating. Binding of competitive antagonists, such as the glycine site antagonist DCKA and the glutamate site antagonist D-AP5, stabilizes an open cleft conformation that is incapable of triggering channel gating (Fig. 5 B).

The stabilization of the NMDA receptor ABDs in a closed cleft conformation by agonist binding and in an open cleft conformation by competitive antagonist binding is similar to that found for the AMPA and kainate receptor ABDs (Pehlsgaard et al., 2011; Kumar and Mayer, 2013; Karakas et al., 2015). However, one notable difference exists. Multiple structures of AMPA receptor ABDs in complex with partial agonists show partial domain closure that correlates with their efficacy (Pehlsgaard et al., 2011). In contrast, multiple structures of ABD with bound partial agonists, such as D-cycloserine, ACPC, and ACBC in GluN1 and NMDA and Pr-NH2PSG in GluN2 show virtually identical degrees of domain closure compared with structures with full agonists (Inanobe et al., 2005; Vance et al., 2011; Hansen et al., 2013). However, these crystal structures capture only one conformation of the isolated ABDs, which may be influenced by the lack of interacting domains (ATD and TMD) and is further stabilized by contacts in the crystal lattice. This caveat to crystal structures of the isolated ABDs is highlighted by recent single-molecule FRET and molecular dynamics studies that provide insight into the dynamic behavior of the NMDA receptor ABDs (Yao et al., 2013; Dai et al., 2015; Dai and Zhou, 2015; Dolino et al., 2015, 2016). These studies suggest that the ABDs fluctuate between open and closed cleft conformations even in the absence of agonist (i.e., the apo state). However, binding of full agonists changes the energy landscape for ABD conformations to strongly favor a fully closed conformation, whereas binding of partial agonists is less efficient in changing this landscape, thereby enabling the ABD to adopt conformations with intermediate domain closure more frequently than full agonists. Hence, a conformational selection mechanism is likely to account for partial agonism in NMDA receptors despite the lack of crystallographic data showing intermediate domain closure for partial agonists.

**Structures of intact tetrameric NMDA receptors**

The first structures of intact NMDA receptors (GluN1/2B extracellular domains and TMDs) confirmed the hypothesized domain organization and showed that GluN1 and GluN2B subunits exist in an alternating pattern (i.e., 1-2-1-2) within the tetrameric assembly (Karakas and Furukawa, 2014; Lee et al., 2014; Fig. 6). These studies also confirmed that the NMDA receptor structure shares certain characteristics with AMPA and kainate receptors. First, the receptor subunits adopt a layered structure, with one layer formed by TMDs and two extracellular layers formed by ABD heterodimers and ATD heterodimers. Second, the TMDs have a quasi-fourfold symmetry, whereas the extracellular portion shows twofold symmetry between the two ABD heterodimers and ATD heterodimers in a dimer-of-dimer arrangement. Thus, there is a symmetry mismatch between the TMD layer and the extracellular layers of the receptor. Third, there is a remarkable subunit crossover between the ABD layer and the ATD layer (Fig. 6). In addition, the NMDA receptor has several unique structural features when compared with AMPA and kainate receptors (Karakas and Furukawa, 2014; Lee et al., 2014). For example, there are extensive contacts between the two GluN1/2 ABD heterodimers that are not present in AMPA and kainate receptor structures. These contacts may provide the structural basis of the GluN2 subunit dependence of glycine potency. In addition, the NMDA receptor ATDs show a different arrangement, leading to distinct subunit interfaces compared with AMPA and kainate receptors. Importantly, the ATDs form extensive contacts with the upper lobe of the ABD whereas the ATD–ABD interactions are minimal in AMPA and kainate receptors. These interactions give the NMDA...
receptor a more compact “hot air balloon–like” appearance, which is distinct from the more Y-shaped AMPA and kainate receptors. The ABD–ATD interactions also create a protein–protein interface at which modulators can bind (Khatri et al., 2014; Kaiser et al., 2018). A recent study also showed that the motif encoded by exon 5, which controls pH sensitivity, deactivation time course, and agonist potency, is also located at the ABD–ATD interface and modulates the ABD–ATD interaction (Regan et al., 2018). The structure of the NMDA receptor thus reveals unique intra- and interdomain contacts that provide a framework for understanding allosteric interactions between subunits, as well as allosteric modulation by small-molecule ligands.

Although the crystallographic structures of intact NMDA receptors advance our understanding of the structure–function relationship, they nevertheless capture only a low energy conformation among the many conformations that the NMDA receptor moves through in route to activation. In these crystal structures, glycine and glutamate were bound to GluN1 and GluN2B, respectively, and the GluN2B-selective negative allosteric modulator ifenprodil was bound to the interface between GluN1 and GluN2B ATDs (Karakas and Furukawa, 2014; Lee et al., 2014). The structures represent the agonist-bound, inhibited receptor with the ion channel closed. However, recent cryo-EM data have described multiple conformations in the extracellular region, providing the first dynamic pictures of NMDA receptor conformational changes and insight into the structural mechanism of receptor activation and allosteric modulation (Tajima et al., 2016; Zhu et al., 2016). Unfortunately, the TMDs for the active and antagonist-bound states are not well resolved in the cryo-EM structures, limiting mechanistic insights into gating and antagonism. However, in the active conformation, distances between the residues that are in proximity of the TMDs increase as much as ∼20 Å in the context of the heterotetramer (Fig. 6 C). This “dilation” of the gating ring likely generates sufficient tensions in the ABD–TMD loops for rearrangement of the helices that form the gate (Kazi et al., 2014; Twomey and Sobolevsky, 2018). This tension can lead to reorientation of the M3 helix in AMPA receptors as well as a kink at an alanine residue that appears to serve as a hinge. Whether or not gating of NMDA receptor ion channels involves similar conformational alterations of the ABD–TMD linker and the TMD demonstrated in the recent AMPA receptor structures (Twomey and Sobolevsky, 2018) remains to be seen, although the gating motifs are highly conserved. Nevertheless, given that the relative orientation of the ABDs and TMDs is distinct in NMDA receptors, structural data are required to evaluate whether these ideas transfer between AMPA and NMDA receptors.

**Figure 6. Structure of the intact NMDA receptors.** (A) Structure of the glycine- and glutamate-bound GluN1-1b/2B NMDA receptor without CTDs (Protein Data Bank accession no. 5FXI; Tajima et al., 2016). (B) The GluN1 (1) and GluN2 (2) subunits are arranged as a dimer of heterodimers at the ATD and ABD layers in a 1-2-1-2 fashion. Note that the heterodimer pairs are interchanged between the ATD and ABD layers (i.e., subunit crossover). In the TMD layer, the GluN1 and GluN2 subunits are arranged as a tetramer with pseudo-fourfold symmetry. (C) Comparison of the two major conformational states observed in the presence of glycine and glutamate by cryo-EM/single-particle analysis. Shown in spheres are the Cα of the gating ring residues, GluN1-1b Arg684 and GluN2B Glu658, which are adjacent to the pore-forming M3 transmembrane helices. In the nonactive (Protein Data Bank accession no. 5FXI; Tajima et al., 2016) and active (Protein Data Bank accession no. 5FXG; Tajima et al., 2016) conformations, the distances between the two GluN2B Glu658 Cα atoms are ∼29 Å and ∼45 Å, respectively, indicating that degrees of tension in the ABD–TMD loops are different.
Control of NMDA receptor function by the ATD

The ATD adopts a bilobed structure, which is unrelated to the ABD, with R1 and R2 referring to upper and lower lobes, respectively (Karakas et al., 2009, 2011). Furthermore, there is a unique dimer-of-dimer arrangement of the NMDA receptor ATDs compared with the ATDs in AMPA and kainate receptors (Karakas and Furukawa, 2014; Lee et al., 2014; Meyerson et al., 2014; Sobolevsky, 2015; Tajima et al., 2016; Zhu et al., 2016). This arrangement, which is revealed in crystal and cryo-EM structures of intact iGluRs, is characterized by a protein–protein interface formed by the upper R2 lobes from the GluN1 and GluN2 subunits, whereas the lower R1 lobes, which connect to the ABDs, are almost completely separated.

Many of the GluN2-specific differences between NMDA receptor subtypes are caused by sequence variation in the GluN2 almost completely separated.

Functional and structural studies have converged on a structural model for NMDA receptor modulation by Zn2+ and ifenprodil, where modulator binding regulates receptor function through rearrangement of the ATD layer and GluN2 ATD clamshell opening and closing (Sirrieh et al., 2013, 2015a). In GluN1/2B, opening of the ATD bilobes robustly alters inter-GluN1/GluN2 subunit arrangement within the ATD, which results in a ∼13° rotation between the GluN1/2B ATD dimers and dilation of the gating ring (Tajima et al., 2016). NAMs such as ifenprodil and zinc favor the closure of the bilobed GluN2B ATD thereby “locking” the subunit arrangement in a way that prevents dilation of the gating ring. Interestingly, the zinc-bound GluN2A ATD is ∼13° more open compared with the zinc-bound GluN2B ATD (Karakas et al., 2009; Romero-Hernandez et al., 2016). This may explain in part the observation that the extent of zinc inhibition is smaller in GluN2A than GluN2B (Rachline et al., 2005).

NMDA receptors containing GluN1 with exon 5 (e.g., the GluN1-1b splice variant) have reduced sensitivity to all three allosteric modulators (Zn2+, ifenprodil, and spermine; Traynelis et al., 1995; Mott et al., 1998; Yi et al., 2018). In recent cryo-EM structures, the 21 amino acids encoded by exon 5 are placed just above the GluN1-GluN2 AB heterodimer interface between the ATD and ABD layers, positioned to influence allosteric interactions between GluN2 ATD clamshell motions and GluN1-GluN2 ABDs (Regan et al., 2018). Furthermore, GluN2C residues from both the ATD and ABD that influenced the activity of PYD-106, a GluN2C-selective positive allosteric modulator (PAM), have been identified and molecular modeling proposed a modular binding site located in a pocket at the ATD–ABD interface of GluN2C (Khatri et al., 2014; Kaiser et al., 2018). These studies all point to the ATD as the major structural determinant of GluN2-specific variation among NMDA receptor subtypes. For this reason, allosteric modulation of NMDA receptors by the ATD is intensely investigated, and drug discovery studies are poised to identify novel ATD ligands with therapeutic potential.

Ligand binding to the ATD

Crystal structures have demonstrated that GluN2B-selective negative allosteric modulators (NAMs), such as ifenprodil and Ro 25-6981, bind to a modulatory site located at the subunit interface between GluN1 and GluN2B ATDs (Karakas et al., 2011; Karakas and Furukawa, 2014; Lee et al., 2014; Stroebel et al., 2016). These crystal structures revealed that only one residue in this modulatory site is different between GluN2A and GluN2B subunits, but sensitivity to ifenprodil is not introduced by converting this or other residues in GluN2A to that in GluN2B (Karakas et al., 2011; Burger et al., 2012). This stems from the fact that the intersubunit arrangements in GluN1/2A and GluN1/2B ATD heterodimers are distinct from each other, as demonstrated in the recent crystal structure of the GluN1/2A ATD heterodimer (Romero-Hernandez et al., 2016). Specifically, the “pocket” in the GluN1/GluN2 subunit interface is ideally sized to accommodate ifenprodil analogues in GluN1/2B, whereas such a pocket is absent in GluN1/2A because of the different subunit arrangement characterized by a ∼10° rotation compared with GluN1/2B. Multiple lines of investigation, including cryo-EM structures of intact NMDA receptors, functional studies, and computational analyses, suggest that ifenprodil inhibition involves closure of the GluN2B ATD bilobes with accompanying changes in the arrangement of the GluN1/2B ATD heterodimers (Burger et al., 2012; Tajima et al., 2016), indicating that both clamshell conformation and subunit arrangement are coupled to function of the NMDA receptor ion channel.

Channel gating in NMDA receptors

All three transmembrane helices (M1, M3, and M4) and the membrane-reentrant pore-forming loop (M2) are involved in the process of pore opening (i.e., channel gating; Schneegasser and Ascher, 1997; Krupp et al., 1998; Villarroel et al., 1998; Ren et al., 2003; Talukder et al., 2010; Kazi et al., 2013; Ogden and Traynelis, 2013; Alsaloum et al., 2016). The transmembrane helix M3 forms a helical bundle crossing that physically occludes the pore, and thus M3 helices must change their position before ions can pass through the channel pore (Jones et al., 2002; Yuan et al., 2005; Chang and Kuo, 2008). The M3 transmembrane helix contains nine amino acids (SYTANAFF) that are almost fully conserved in iGluRs throughout the animal kingdom. Multiple structural and functional studies suggest that these residues comprise the activation gate and that dilation of the M3 helical bundle crossing is thought to be the key change that allows ion conduction (Beck et al., 1999; Sobolevsky et al., 2002a; Chang and Kuo, 2008).

What sequence of events leads to M3 rearrangement? Agonist binding to the bilobed ABDs involves a clamshell closure around the ligands that must be the first step in a sequence of
conformational changes that lead to gating. These are followed by multiple short-lived, intermediate conformations that precede a rapid transition from the closed to the open state of the ion channel, inferred by brief, kinetically distinguishable closed states in the single-channel record and the relatively slow time course for receptor activation by supersaturating agonist (Banke and Traynelis, 2003; Popescu et al., 2004; Auerbach and Zhou, 2005; Erreger et al., 2005a; Schorge et al., 2005; Kussius and Popescu, 2009; Fig. 7). However, there is poor understanding of the protein conformations that represent the rate limiting steps en route to channel opening. Moreover, the lifetimes of some of these intermediate conformations are brief, suggesting they are unlikely to be captured in crystal structures or cryo-EM studies, leaving functional experiments as the most feasible (yet imperfect) way to glean clues as to how these changes might control channel opening. Recent functional studies have built explicit models of channel activation in which specific conformations are hypothesized for each of the four subunits (Gibb et al., 2018). Moreover, work with disease-causing mutations identified in human patients has provided key insights into the elements that comprise the gating control mechanism. Residues in the region connecting the S1 segment of the ABD with the M1 transmembrane helix (i.e., the pre-M1 linker) are invariant in the healthy population, and a locus for disease-associated mutations in various neurological diseases (Ogden et al., 2017). In addition, the region connecting the S2 segment of the ABD with the M4 transmembrane helix (i.e., the pre-M4 linker) also appears to be implicated in patients with NMDA receptor missense mutations, and both the pre-M1 and pre-M4 linkers are close enough to be in contact with the conserved SYTANLAAF motif in the M3 helical bundle crossing. These three elements (pre-M1, SYTANLAAF, and pre-M4) appear positioned to form a gating control mechanism (Chen et al., 2017), and it is possible that kinetically distinct conformational states may be the result of rearrangements of this triad of interacting regions. Moreover, the different amino acid sequences for pre-M1 and pre-M4 that exist for GluN1 and GluN2 as well as different positions of these elements in relation to the gating ring could lead to distinct lifetimes for intermediate conformations that must be traversed before rapid pore dilation (Erreger et al., 2005a; Dravid et al., 2008; Kussius and Popescu, 2009; Amicoservio and Popescu, 2010; Vance et al., 2012).

**Kinetic models for NMDA receptor activation**

The sequence of protein conformational changes that trigger channel gating can be described as reaction schemes (i.e., kinetic models) with agonist binding steps and transitions between different conformational states of the receptor (Fig. 8). The first widely applied kinetic model for NMDA receptor gating was solely designed to account for the time course of the macroscopic current response and consisted of two identical but independent glutamate binding steps, one desensitized state, one closed state, and one open state (Lester and Jahr, 1992). This simple kinetic model appeared to effectively capture key features of macroscopic NMDA receptor responses but was not intended to describe the complexity observed in single-channel recordings (Ascher et al., 1988; Howe et al., 1991; Traynelis and Cull-Candy, 1991; Gibb and Colquhoun, 1992). Furthermore, the usefulness of the Lester and Jahr model was limited by the lack of glycine-binding steps required for receptor activation. Kinetic models that account for both glutamate- and glycine-binding steps as well as intersubunit interactions between the glutamate and glycine ABDs have also been developed (Benveniste et al., 1990), and these models could capture additional features of the time course of NMDA receptors, including glycine-dependent desensitization (see below).

Newer, more complex kinetic models have been proposed that better describe single-channel data by incorporating multiple steps between binding and gating (Banke and Traynelis, 2003; Popescu et al., 2004; Auerbach and Zhou, 2005; Erreger et al., 2005a; Schorge et al., 2005). Investigations of macroscopic and single-channel responses to partial and full agonists suggest that agonist binding to either GluN1 or GluN2 controls distinct steps in the kinetic model (Banke and Traynelis, 2003; Auerbach and Zhou, 2005; Erreger et al., 2005a; Schorge et al., 2005; Fig. 8), although it has also been suggested that partial agonists can impact all pre gating steps irrespective of the subunit they bind to (Kussius and Popescu, 2009; Kussius et al., 2010). In some of these models, the actions of allosteric modu-
lators are accounted for by explicitly representing the modula-
tor bound and unbound receptor as independent states (Banke et al., 2005; Erreger and Traynelis, 2008; Amico-Ruvio et al., 2011). Other models for channel blockers and other use-depen-
dent modulators have been described that exclusively allow
modulators to bind to the open state (Huettner and Bean, 1988;
MacDonald et al., 1991; Blanpied et al., 1997, 2005; Dravid et al., 2007; Kussius et al., 2009; Paganelli and Popescu, 2015;
Glasgow et al., 2017).

The ability of AMPA receptor subunits to operate semi-inde-
pendently (Rosenmund et al., 1998; Jin et al., 2003; Kristensen et al., 2011) and the modular domain architecture of glutamate
receptor structures raise the possibility that independent con-
formational changes in different subunits may progress within
the sequence of steps leading to channel opening (Gibb et al., 2018). Some kinetic models suggest that such subunit-specific conformational changes are required in all four NMDA recep-
tor subunits to trigger channel gating and that these structural
changes can occur in any order to arrive at an intermediate
state that can subsequently transition to the open state of the
ion channel (Banke and Traynelis, 2003; Auerbach and Zhou,
2005; Erreger et al., 2005a,b; Schorge et al., 2005). Other mod-
els account for macroscopic and single-channel responses by
including a few sequential gating steps in a linear kinetic model
with an implicit order for slow and fast gating steps (Popescu et al., 2004; Kussius and Popescu, 2009). These models have been
used to explore the kinetic aspects of modal gating (Zhang et al.,
2008; Iacobucci and Popescu, 2017a), an intriguing phenome-
non that is readily apparent in cell-attached recordings from
GluN1/GluN2A receptors. Gating modes are defined by different
open probabilities and open times and have been described for
GluN1/2A and GluN1/2B receptors (Popescu and Auerbach, 2003;
Popescu et al., 2004; Amico-Ruvio and Popescu, 2010; Popescu,
2012) but are rarely observed in GluN1/2D (Vance et al., 2013).

**Figure 8.** Application of a gating reaction mechanism of NMDA receptors. (A) Individual responses from a recombinant GluN1/2B channel in an excised
outside-out patch activated by 1 ms application of maximally effective glutamate and glycine (indicated by the gray vertical bar and the open tip recording above
the channel recordings). The patch contained a single active channel, which allowed analysis of the variable delay before channel opening. NMDA receptors
bind agonist rapidly and subsequently open after a multimillisecond delay that reflects transition through kinetically distinct protein conformations before
pore dilation (i.e., channel gating). Note that although application of maximal glutamate and glycine always produces a binding event, not all binding events
lead to channel opening. Reproduced from Erreger et al. (2005a). (B) The cumulative plot of latency to opening after application of 1 mM glutamate for 1 ms.
(C) The average of all individual recordings of single activations produced a macroscopic waveform with a characteristic rise time. (D) Evaluation of closed
periods within the GluN1/2B activation suggested a model where two pregating steps can occur in any order and explosive opening of the pore, which occurs
faster than the resolution of the recordings, is assumed to happen instantaneously once both pregating steps have been traversed. (E) Simulation of a single
activation for a GluN1/2B channel (using the model in D) illustrates how brief gaps can contain information about forward rates for the fast kinetically distinct
pregating step. The color above the simulation indicates occupancy in the corresponding closed state of the model in D. The slow step often reverses again
through the fast state (green) before reopening.
Although the mechanism remains elusive, mode switching has been proposed to influence the time course of the synaptic current (Zhang et al., 2008).

All these kinetic models for NMDA receptor gating that faithfully describe both macroscopic responses and single-channel data require both multiple pregating steps and multiple open states. The interpretation of this observation is that ion channel opening in NMDA receptors is not directly coupled to agonist-induced ABD closure; instead, the receptor must proceed through a sequence of conformational changes that couple agonist binding to ion channel gating.

**Structural determinants of ion permeation and channel block**

The ion channel pore in NMDA receptors can be divided into the intracellular and extracellular vestibules separated by a narrow constriction (Fig. 9). The narrow restriction resides approximately halfway across the membrane at the apex of the membrane reentrant loop M2 (i.e., the Q/R/N site) and is often referred to as the selectivity filter because of its role as key determinant of Ca2+ permeability, single-channel conductance, and channel block (Wollmuth and Sobolevsky, 2004; Traynelis et al., 2010; Glasgow et al., 2015). The residue at the Q/R/N site is asparagine (N) in both GluN1 and GluN2, but the contribution of this residue to ion permeation is asymmetric between GluN1 and GluN2 subunits (Burnashev et al., 1992; Wollmuth et al., 1996, 1998; Sobolevsky et al., 2002b). This is because the narrow constriction is formed by the Q/R/N site asparagine in GluN1 but by the asparagine residue adjacent to the Q/R/N site (i.e., Q/R/N +1 site) in GluN2. The asymmetric contribution by GluN1 and GluN2 is revealed by substitutions of the Q/R/N site residue in GluN2 that have weak effects on Ca2+ permeability and dramatically reduce Mg2+-block, whereas the same substitutions of the Q/R/N site residue in GluN1 dramatically reduce Ca2+ permeability and have weak effects on Mg2+ block (Burnashev et al., 1992; Wollmuth et al., 1998). However, mutations at the Q/R/N +1 site in GluN2 strongly reduce Mg2+-block (Wollmuth et al., 1998). Functional data therefore suggest a structural asymmetry, where the apexes of M2 in GluN1 and GluN2 are slightly staggered (Sobolevsky et al., 2002b). Diheteromeric GluN1/3 receptors have glycine/arginine residues at the Q/R/N and Q/R/N +1 and show both markedly reduced Ca2+-permeability and Mg2+-block compared with GluN1/2 receptors (Cavara and Hollmann, 2008; Henson et al., 2010; Low and Wee, 2010; Pachernegg et al., 2012; Kehoe et al., 2013). Recent data describing the pore of the AMPA receptor in the open state reinforce the idea that the apex of the reentrant loops form a constriction that impacts ion permeation (Twomey et al., 2017). The structural basis for this functional asymmetry will require high-resolution images of the NMDA receptor in the open state.

**Determinants of ion permeation**

NMDA receptor ion channels are permeable to the physiologically relevant Ca2+, Na+, and K+ ions. The different NMDA receptor subtypes display similar permeability to Na+ and K+ ions (PNa/PK = 1.14) but are more permeable to Ca2+ relative to monovalent ions (PCa/PNa = 1.8–4.5), with variation in Ca2+ permeability that depends on the GluN2 subunit (Burnashev et al., 1995; Schneggenburger, 1996, 1998; Sharma and Stevens, 1996; Jatzke et al., 2002). However, NMDA receptors also exhibit block by external Ca2+, despite being highly Ca2+ permeable, which can be observed as a reduction in channel conductance in single-channel data (Premkumar and Auerbach, 1996; Wylle et al., 1996; Premkumar et al., 1997; Dravid et al., 2008). The concurrent block by Ca2+ and the high Ca2+ permeability are not incompatible properties but are expected if multiple Ca2+-binding sites are located in the ion channel pore of NMDA receptors (Premkumar and Auerbach, 1996; Sharma and Stevens, 1996). Studies have suggested that one Ca2+-binding site is located at the Q/R/N site, whereas another, more external Ca2+-binding site could be formed by a cluster of charged DPEER residues in GluN1 (Watanabe et al., 2002; Karakas and Furukawa, 2014). The external Ca2+-binding site is located at the external entrance to the ion channel above the transmembrane helix M3 of GluN1. Although structural elements of Ca2+ permeation in GluN1/N2 subunits of NMDA receptors can contribute to Ca2+ block, other loci, such as the Q/R/N site, contribute most to Mg2+ block.
Subunits have been identified, the mechanism of Ca²⁺ permeation remains unknown.

**Determinants of channel block**

GluN1/2A and GluN1/2B channels are more strongly blocked by extracellular Mg²⁺ than GluN1/2C and GluN1/2D channels (Monyer et al., 1994; Kuner and Schoepfer, 1996; Qian et al., 2005; Clarke and Johnson, 2006; Siegler Retchless et al., 2012). This channel block is highly dependent on the membrane potential (i.e., voltage dependent), and the IC₅₀ values (the concentrations that produce half-maximal inhibition) for block by external Mg²⁺ are 2 µM, 2 µM, 14 µM, and 10 µM for GluN1/2A, GluN1/2B, GluN1/2C, and GluN1/2D, respectively, at a holding potential of −100 mV (Kuner and Schoepfer, 1996). The dependency of Mg²⁺ block on the GluN2 subunit is influenced by multiple structural elements, but a main determinant appears to be a single residue at the S/L site located in the M3 transmembrane helix (Siegler Retchless et al., 2012). The residue at the S/L site, which is a serine in GluN2A/B and a leucine in GluN2C/D, is not lining the ion channel pore but has been suggested to interact with tryptophan residues in the membrane reentrant loop M2 of GluN1 (Siegler Retchless et al., 2012). This interaction between GluN1 and the GluN2 S/L site also appears to be a key determinant of GluN2 subunit–specific variation in channel conductance and Ca²⁺ permeability (Siegler Retchless et al., 2012). Although important insight into the structural mechanism of GluN2 subunit–dependent control of Mg²⁺ block is still missing, it is possible that structural elements, including the GluN2 S/L site, govern Mg²⁺ block by influencing binding sites for permeant ions in the channel pore (Antonov and Johnson, 1999; Zhu and Auerbach, 2001a,b; Qian et al., 2002; Qian and Johnson, 2006).

**Channel block by organic cations**

The NMDA receptor ion channel pore can be blocked in a voltage-dependent manner by a wide range of organic cations with different chemical structures (Huetter and Bean, 1988; Brackley et al., 1993; Parsons et al., 1995). These compounds almost exclusively block open channels in activated NMDA receptors and are positively charged at physiological pH, a mechanism of channel block termed uncompetitive or use dependent. In general, the open channel blockers can be classified into three categories based on their interaction with the channel: (1) “foot-in-the-door” or sequential blockers (e.g., aminocyclidine derivatives and tetrapentylammonium) can only bind to the channel when it is open and prevent channel closure when bound (Benveniste and Mayer, 1995; Sobolevsky, 1999; Sobolevsky et al., 1999; Bolshakov et al., 2003; Barygin et al., 2009); (2) partial trapping blockers (e.g., amantadine and memantine) obstruct channel closure but are unable to completely prevent it (Blanpied et al., 1997, 2005; Chen and Lipton, 1997; Mealing et al., 1999; Kotermanski et al., 2009; Johnson et al., 2015); and (3) trapping blockers (e.g., Mg²⁺, ketamine, phencyclidine [PCP], and MK-801) are trapped inside the channel pore as it closes, and agonists can unbind while the trapping blocker remains bound (Sobolevsky and Yelshansky, 2000; Poulsen et al., 2015). Some channel blockers have also been shown to facilitate channel closure, presumably by interacting with the channel gate (Blanpied et al., 2005; Johnson et al., 2015). Channel blockers proposed to have bifunctionality include nitromantine derivatives that bind the ion channel pore, facilitating the targeting of a nitro group to a redox-mediated regulatory site on the receptor (Takahashi et al., 2015).

In general, the open channel blockers are considered nonselective among NMDA receptor subtypes (Dravid et al., 2007), but some channel blockers, such as ketamine and memantine, display 5- to 10-fold preference for GluN2C/D-containing receptors over GluN2A/B-containing receptors in the presence of 1 mM extracellular Mg²⁺ (i.e., under physiological conditions; Kotermanski and Johnson, 2009). NMDA receptor channel blockers have robust neuroprotective effects in animal models of CNS disorders that involve excessive NMDA receptor activation, such as stroke, epilepsy, and traumatic brain injury. However, clinical trials have not been successful because of dose-limiting side effects, patient heterogeneity, and a narrow temporal window for intervention that could have confounded interpretation (Ikonomidou and Turski, 2002; Farin and Marshall, 2004; Muir, 2006; see also Table S2 in Yuan et al., 2015). NMDA receptor channel blockers that bind with high affinity, such as ketamine and PCP, are typically dissociative anesthetics, and their clinical use is limited by psychomimetic side effects. Nonetheless, there is an intense interest in use of ketamine or similar molecules for the treatment of major depressive disorder because of several promising clinical trials in recent years based on the discovery of antidepressant effects for NMDA receptor antagonists (Niciu et al., 2014; Abdallah et al., 2015; Zanos et al., 2018).

Channel blockers such as memantine, which is approved in the treatment of moderate to severe Alzheimer’s disease, have lower affinity than ketamine and PCP and show faster blocking/unblocking kinetics (Parsons et al., 1993). These kinetic properties have been suggested to contribute to an improved therapeutic index with respect to psychomimetic effects, perhaps because of reduced channel block during normal synaptic transmission (Chen and Lipton, 2006), although the mechanism by which memantine may contribute to a symptomatic benefit in Alzheimer’s disease is not well understood. Interestingly, Glasgow et al. (2017) have proposed that memantine stabilizes occupancy of a desensitized state of GluN1/2A receptors, whereas ketamine reduces occupancy of a GluN1/2B desensitized state (Glasgow et al., 2017). Thus, the affinity of these blockers for their binding site in the channel may be allosterically affected by the conformational changes in the receptor protein associated with desensitization. Given the prevalence of triheteromeric GluN1/2A/2B receptors in the brain, it will be important to evaluate memantine and ketamine block at these triheteromeric receptors.

**Endogenous mechanisms of functional modulation**

NMDA receptors are complex macromolecular membrane-bound protein complexes, and their functional properties and membrane trafficking can be altered by extracellular ions, phosphorylation, and intracellular binding proteins. Additionally, the differences between various diheteromeric and triheteromeric NMDA receptor subtypes create selective actions of many of these types of modulation. Here, we will describe various forms of endogenous regulation of NMDA receptor function.
Extracellular Zn$^{2+}$ inhibits NMDA receptor function with an IC$_{50}$ of $\sim 50$ nM, corresponding to a pH of $\sim 7.3$ (Giffard et al., 1990; Traynelis and Cull-Candy, 1990, 1991; Vyklický et al., 1990). Thus, neuronal NMDA receptors are tonically inhibited by protons at physiological pH and are therefore poised to respond to small changes in extracellular pH that can occur under physiological conditions caused by release of protons from acidic synaptic vesicles or movement of protons across the plasma membrane by pumps (Chesler, 2003). Furthermore, pathological conditions, including seizure and ischemia, produce extracellular acidification, which can decrease pH to levels that strongly inhibit NMDA receptor function (Chesler, 2003).

The sensitivity of the NMDA receptors to inhibition by extracellular protons depends on the GluN2 subunit (Traynelis et al., 1995), with GluN2A-, GluN2B-, and GluN2D-containing NMDA receptors showing proton IC$_{50}$ values near physiological pH (7.0–7.4). In contrast, GluN2C-containing receptors are less sensitive to changes in pH, with an IC$_{50}$ value near pH 6.0 (Traynelis et al., 1995; Low et al., 2003). NMDA receptors that include GluN1 subunits containing the alternatively spliced exon 5 in the ATD (i.e., GluN1-1b) are notably less sensitive to protons (Traynelis et al., 1995). Proton inhibition is voltage-independent, and without effect on glutamate potency; low pH produces modest shifts in the glycine potency (Tang et al., 1990; Traynelis and Cull-Candy, 1990, 1991; Traynelis et al., 1995). The structural determinants underlying proton inhibition are unknown, although mutations at the ABD interface, linkers to pore-forming elements, and within the M2 reentrant loop can all influence pH sensitivity (Low et al., 2003; Gielen et al., 2008). This suggests that NMDA receptor gating is tightly coupled to proton inhibition of the receptor. This idea is consistent with the observation that channel blockers appear to sense the protonation state of the receptor (Dravid et al., 2007).

The actions of ATD modulators appear to involve a change in the pKa of the proton sensor that leads to enhancement or reduction of tonic proton inhibition at physiological pH. Thus, both Zn$^{2+}$ and ifenprodil enhance proton sensitivity, which will increase tonic inhibition at resting pH (Pahk and Williams, 1997; Mott et al., 1998; Traynelis et al., 1998; Choi and Lipton, 1999; Erreger and Traynelis, 2008; Bhatt et al., 2013). In contrast, the binding of extracellular polyamines reduces the sensitivity to extracellular pH, resulting in potentiation due to reduced tonic inhibition at resting pH (Pahk and Williams, 1997; Traynelis et al., 1998; Choi and Lipton, 1999; Low et al., 2000; Erreger and Traynelis, 2008). Interestingly, triheteromeric GluN1/2A/2B receptors retain a high-affinity Zn$^{2+}$ binding, although there is reduced inhibition at maximally effective concentrations of Zn$^{2+}$ (Hatton and Paoletti, 2005; Hansen et al., 2014; Stroebel et al., 2014). Higher concentrations of Zn$^{2+}$ can produce a voltage-dependent channel block (Williams, 1996), but it remains unclear whether changes in extracellular Zn$^{2+}$ in brain tissue are large enough to produce voltage-dependent channel block (Vogt et al., 2000; Anderson et al., 2015).

The affinity for Zn$^{2+}$ at the GluN2A ATD is high enough such that Zn$^{2+}$ contamination in physiological levels of salts can produce significant inhibition (Paoletti et al., 1997). The effects of contaminant Zn$^{2+}$ in functional experiments can be removed by inclusion of even low concentrations of divalent ion chelators, such as 10 $\mu$M EDTA. The high affinity of such chelators for Zn$^{2+}$ means that even low micromolar levels of chelator will bind virtually all of the nanomolar-contaminating Zn$^{2+}$ ions but exert minimal effects on millimolar concentrations of Ca$^{2+}$ or Mg$^{2+}$ (Anderson et al., 2015).

**Positive and negative allosteric modulation by neurosteroids**

Several endogenous neurosteroids positively and negatively modulate NMDA receptor activity (Traynelis et al., 2010), although the actions of these lipophilic molecules are complex. For instance, pregnenolone sulfate has dual actions on NMDA receptor responses, having both inhibitory and potentiating activity over a wide range of potencies (Horak et al., 2006). The potentiating actions of pregnenolone sulfate are most prominent when applied before receptor activation, whereas inhibitory actions arise when applied continuously (Horak et al., 2006). The dual actions of pregnenolone sulfate lead to divergent effects depending on the GluN2 subunit; when applied during steady-state NMDA receptor responses, GluN1/2A and GluN1/2B are potentiated, whereas GluN1/2C and GluN1/2D are inhibited.

Other neurosteroid analogues, such as pregnanolone sulfate, inhibit all NMDA receptor subtypes (i.e., they are pan-inhibi-
in a manner that is independent of glycine, Zn\(^{2+}\), and Ca\(^{2+}\). NMDA receptors can also desensitize in the continued presence of agonist by a mechanism thought to involve a conformational change to a stable and long-lived agonist-bound closed state. This is the result of a positive intrasubunit allosteric coupling between glutamate- and glycine-binding sites, such that the current will initially rise to a peak and then decline to a new equilibrium as glycine unbinds from the receptor after the allosteric reduction in glycine affinity. The time course for the desensitization is dictated by glycine unbinding (time constant \(\sim 0.3\) s) and is temporally close to the synaptic NMDA receptor time course, raising the possibility that glycine-dependent desensitization could impact synaptic signaling when glycine is subsaturating (Berger et al., 1998). Recent structural data for NMDA receptors provide plausible models for the negative allosteric coupling between glutamate- and glycine-binding sites, given their close proximity (Karakaš and Furukawa, 2014; Lee et al., 2014; Tajima et al., 2016; Zhu et al., 2016). However, the structural features that enable glycine-dependent desensitization remain poorly understood.

### Zn\(^{2+}\)-dependent NMDA receptor desensitization

Extracellular Zn\(^{2+}\) inhibits GluN1/GluN2A and GluN1/GluN2B receptors in a voltage-independent manner through a binding site located in the ATD (Williams, 1996; Traynelis et al., 1998; Choi and Lipton, 1999; Fayyazuddin et al., 2000; Low et al., 2000; Paolletti et al., 2000; Rachline et al., 2005; Karakaš et al., 2009). However, NMDA receptors also display a rapid component of desensitization in the presence of extracellular Zn\(^{2+}\) that occurs by a mechanism similar to glycine-dependent desensitization (Chen et al., 1997). This is the result of a positive intrasubunit allosteric interaction between glutamate binding to the GluN2 AB and Zn\(^{2+}\) binding to the GluN2A ATD (Zheng et al., 2001; Erreger and Traynelis, 2005). As a result, in the presence of subsaturating concentrations of Zn\(^{2+}\), the glutamate-induced increase in Zn\(^{2+}\) affinity will cause a relaxation of the response to a new equilibrium as more Zn\(^{2+}\) ions bind and inhibit the receptor. The time course for Zn\(^{2+}\)-dependent desensitization therefore follows the time course for Zn\(^{2+}\) binding.

### Ca\(^{2+}\)-dependent NMDA receptor inactivation

NMDA receptors also undergo Ca\(^{2+}\)-dependent desensitization or inactivation, which requires an increase in intracellular Ca\(^{2+}\) over several seconds (Clark et al., 1990; Legendre et al., 1993; Vylický, 1993; Rosenmund et al., 1995). The magnitude of this form of desensitization varies with different NMDA receptor subtypes; it is most prominent for GluN2A-containing NMDA receptors and more limited for GluN2B- and GluN2C-containing NMDA receptors (Medina et al., 1995; Krupp et al., 1996). The proposed mechanism involves an increase in the intracellular Ca\(^{2+}\) in the vicinity of the NMDA receptor that triggers uncoupling of the receptor from filamentous actin (Rosenmund and Westbrook, 1993). In addition, calmodulin binding to the GluN1 CTD may play a role in this form of desensitization (Ehlers et al., 1996; Rycroft and Gibb, 2002; Iacobucci and Popescu, 2017a); Ca\(^{2+}\)-dependent desensitization is absent in NMDA receptors containing GluN1 splice variants that lack calmodulin-binding sites (Ehlers et al., 1996, 1998) or harbor mutations in calmodulin-binding sites in the GluN1 CTD (Zhang et al., 1998; Krupp et al., 1999).
Conclusion
Recent discoveries from genetic analyses that link NMDA receptors to specific disease conditions, the emerging evidence of the antidepressant effects of NMDA receptor antagonists, and accelerating identification of new subunit-selective modulators have reinvigorated the long-standing interest in NMDA receptors as therapeutic targets. The field now seems poised to achieve new levels of understanding of the functional roles of NMDA receptors in physiology and disease. The rapidly increasing volume of crystallographic and cryo-EM data has created an opportunity to view function through structure, which will inevitably improve our insight to the mechanisms by which agonist binding is linked to channel gating and how different NMDA receptor subunits contribute to the conformational changes that occur during gating and allosteric modulation. These new developments can lead novel perspectives in the NMDA receptor field and create exciting opportunities to study the physiological roles of different diheteromeric and triheteromeric NMDA receptor subtypes in distinct subcellular locations and neuronal populations. These converging advances in NMDA receptor pharmacology, mechanistic understanding of receptor function, and the basis of CNS diseases involving NMDA receptor dysfunction are already catalyzing the development of new therapeutic strategies.

Acknowledgments
This work was supported by grants from National Institutes of Health to S.F. Traynelis (NS036654 and NS065371), K.B. Hansen (GM103546 and NS097536), and L.P. Wollmuth (NS088479).

References
Hansen et al.
Structure and function of NMDA receptors
Journal of General Physiology
https://doi.org/10.1085/jgp.201812032


Talukder, I., P. Borker, and L.P. Wollmuth. 2010. Specific sites within the ligand-binding domain and ion channel linkers modulate NMDA receptor

Hansen et al. Structure and function of NMDA receptors Journal of General Physiology https://doi.org/10.1085/jgp.201812032


